TWST: Sector Recovery Hopes Will Likely Outpace 2026 Execution Reality

Analysts have lifted the implied fair value estimate for Twist Bioscience by about $5 to roughly $38 per share, citing refreshed models that incorporate updated 2026 frameworks, recovering end markets and multiple avenues for growth reflected in recent price target increases from firms across the diagnostic tools peer group.

Analyst Commentary

Recent Street research on Twist Bioscience has centered on refreshed 2026 frameworks, sector rotation within diagnostic tools and how quickly end markets are recovering. Several firms have updated price targets in close succession, with commentary anchored on multiyear visibility, capital spending trends and where the stock fits within a broader tools recovery theme.

Some analysts point to investor sentiment that is gradually improving around tools names with clearer long-term plans, viewing updated 2026 guidance as a key reference point. In this context, Twist is being grouped with companies that are seen as having multiple possible drivers for future revenue, although the details of those drivers and their timing remain subject to execution.

At the same time, research notes flag that sector-level factors such as procedure volumes, capital expenditure patterns and policy questions tied to programs like the Affordable Care Act and Medicare remain important inputs to how Twist is valued. For readers, that means price targets are being framed not only around company-specific assumptions but also around how the broader tools and MedTech complex is expected to respond to these moving pieces.

Bearish Takeaways

Bearish analysts highlight that higher price targets still embed execution risk around 2026 goals, leaving the stock exposed if revenue or margin progress tracks below the frameworks now being used in models.
There is concern that sector rotation into tools could reverse if procedure trends or capital expenditure patterns soften, which could pressure valuation multiples assigned to Twist even if company-specific metrics hold steady.
Policy uncertainty tied to potential changes in programs such as the Affordable Care Act and Medicare is flagged as a risk for tools exposure, raising questions about how sustainable demand and reimbursement will be for parts of Twist’s customer base.
Some cautious views point to the reliance on multiyear scenarios to support current fair value estimates, warning that any delay in end market recovery or slower than expected uptake of Twist’s offerings could lead to lower target prices over time.

What's in the News

Licensing agreement with Invenra for its B-Body bispecific antibody platform, making Twist a co-exclusive provider alongside Invenra and expanding Twist's antibody discovery services (Key Developments).
Twist to pay Invenra an upfront US$5 million in cash and US$15 million in Twist common stock, and to acquire an approximately 6% ownership stake in Invenra through a US$13.8 million preferred stock purchase (Key Developments).
Twist to receive all revenue from bispecific antibody discovery services conducted by Twist and all license revenue related to the platform, while paying Invenra a 20% royalty on license revenue (Key Developments).
Launch of the Twist TrueAmp Library Preparation Kit and Twist PCR-Free WGS Library Preparation Kit, targeting a wide range of sample inputs, including low input and challenging samples, for clinical research and next generation sequencing applications (Key Developments).
Company earnings guidance for fiscal 2026 with expected total revenue of US$435 million to US$440 million, and second quarter fiscal 2026 revenue guidance of US$107 million to US$108 million, with growth of approximately 16% year over year at the midpoints (Key Developments).

Valuation Changes

Fair Value: Implied fair value estimate has risen from $33.00 to about $38.04 per share, an increase of roughly $5.
Discount Rate: The discount rate has edged up slightly from 7.08% to about 7.11%, indicating a modestly higher required return in the models.
Revenue Growth: The revenue growth assumption has been reduced from about 16.37% to roughly 15.33%, reflecting a slightly more conservative outlook for top line expansion.
Net Profit Margin: The net profit margin expectation has shifted from about 16.96% to around 14.76%, reflecting lower modeled profitability over time.
Future P/E: The future P/E multiple has increased from about 26.17x to roughly 34.28x, indicating a higher valuation multiple applied to projected earnings.

2 views

Key Takeaways

Intensifying competition and industry consolidation are driving down margins, pressuring Twist Bioscience to increase spending on innovation and commercialization.
Heavy reliance on a few customers heightens revenue volatility, while operational costs and regulatory risks challenge the path to consistent profitability.
Ongoing product innovation, strategic market expansion, and improved margins position Twist Bioscience for robust long-term growth with increasing profitability and diversified revenue streams.

Catalysts

About Twist Bioscience

Manufactures and sells synthetic DNA-based products.What are the underlying business or industry changes driving this perspective?

The increasing commoditization of DNA synthesis and next-generation sequencing services, driven by rapid advancements in AI-driven protein design and DNA manufacturing, threatens to erode Twist Bioscience's technological differentiation, resulting in sustained pricing pressure and contraction of gross margins over the next several years.
Persistent customer concentration risk remains in both the NGS and SynBio businesses, leaving revenues highly exposed to contract delays or the loss of a handful of large pharma or diagnostic accounts. Recent quarter results already show revenue impacts from single-customer order timing and transitions, foreshadowing potential future volatility and impairing predictability of earnings.
Escalating international trade tensions and the risk of tighter global biosecurity or data privacy regulations could disrupt supply chains, drive up input costs, and increase compliance expenditure for Twist, putting downward pressure on net margins while undermining the company's ability to deliver on global revenue growth targets.
While the company is investing heavily in R&D and platform expansion in pursuit of profitability, persistent high operational expenditures without the realization of scalable profit could result in extended negative net margins, particularly if revenue growth decelerates or fails to outpace rising costs amid an increasingly competitive landscape.
Large, well-capitalized competitors and aggressive industry consolidation threaten to intensify customer acquisition costs and force Twist to accelerate reinvestment into both product innovation and commercial infrastructure. This scenario risks diluting operating leverage, suppressing future earnings per share, and potentially stalling the company's path to sustainable profitability.

Twist Bioscience Earnings and Revenue Growth

Twist Bioscience Future Earnings and Revenue Growth

Assumptions

How have these above catalysts been quantified?

This narrative explores a more pessimistic perspective on Twist Bioscience compared to the consensus, based on a Fair Value that aligns with the bearish cohort of analysts.
The bearish analysts are assuming Twist Bioscience's revenue will grow by 15.3% annually over the next 3 years.
The bearish analysts are not forecasting that Twist Bioscience will become profitable in next 3 years. To represent the Analyst Price Target as a Future PE Valuation we will estimate Twist Bioscience's profit margin will increase from -19.6% to the average US Biotechs industry of 14.8% in 3 years.
If Twist Bioscience's profit margin were to converge on the industry average, you could expect earnings to reach $88.6 million (and earnings per share of $1.35) by about March 2029, up from -$76.6 million today.
In order for the above numbers to justify the price target of the more bearish analyst cohort, the company would need to trade at a PE ratio of 34.6x on those 2029 earnings, up from -35.7x today. This future PE is greater than the current PE for the US Biotechs industry at 15.1x.
The bearish analysts expect the number of shares outstanding to grow by 2.33% per year for the next 3 years.
To value all of this in today's terms, we will use a discount rate of 7.11%, as per the Simply Wall St company report.

Risks

What could happen that would invalidate this narrative?

The company reported significant year-over-year revenue growth across all major segments, including SynBio (7% growth) and NGS (27% growth), as well as expansion into new customer bases and markets, which points to underlying revenue strength and ongoing customer demand.
Gross margin has improved dramatically, rising from 31% to over 53% in two years, with management guiding for continued gross margin expansion, supporting future improvements in net margins and overall profitability.
Twist Bioscience's ongoing product innovation-including internally manufactured primers, new SynBio offerings, and differentiated high-throughput solutions-positions the firm to benefit from long-term secular trends in synthetic biology, which could drive sustained growth in top-line revenue and earnings.
The company is seeing strong adoption within the clinical segment of NGS and emerging growth in minimal residual disease (MRD), with management expecting further commercial launches in 2026 and 2027 that could lead to sequential growth and recurring revenue streams, bolstering earnings stability.
Management highlighted successful customer diversification in both industrial and academic markets, combined with disciplined OpEx management and a clear commitment to reaching adjusted EBITDA breakeven, indicating a strong strategic focus on improving net profits and ensuring sustained financial health.

Valuation

How have all the factors above been brought together to estimate a fair value?

The assumed bearish price target for Twist Bioscience is $38.04, which represents up to two standard deviations below the consensus price target of $50.44. This valuation is based on what can be assumed as the expectations of Twist Bioscience's future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.
However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $58.0, and the most bearish reporting a price target of just $36.0.
In order for you to agree with the more bearish analyst cohort, you'd need to believe that by 2029, revenues will be $600.6 million, earnings will come to $88.6 million, and it would be trading on a PE ratio of 34.6x, assuming you use a discount rate of 7.1%.
Given the current share price of $44.53, the analyst price target of $38.04 is 17.1% lower. Despite analysts expecting the underlying business to improve, they seem to believe the market's expectations are too high.
We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.

Have other thoughts on Twist Bioscience?

Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.

Create Narrative

How well do narratives help inform your perspective?

Disclaimer

AnalystLowTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystLowTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystLowTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.

DNA Synthesis Commoditization And Trade Tensions Will Erode Margins